The role of delamanid in the treatment of drug-resistant tuberculosis.

Article Details

Citation Copy to clipboard

Lewis JM, Sloan DJ

The role of delamanid in the treatment of drug-resistant tuberculosis.

Ther Clin Risk Manag. 2015 May 13;11:779-91. doi: 10.2147/TCRM.S71076. eCollection 2015.

PubMed ID

25999726 [ View in PubMed

]

Abstract

Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.

DrugBank Data that Cites this Article

Drugs

Delamanid

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Delamanid	Deazaflavin-dependent nitroreductase	Protein	Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	No	Substrate	Details

Drug Interactions

Drugs	Interaction
Integrate drug-drug interactions in your software
Delamanid Midostaurin	The metabolism of Delamanid can be decreased when combined with Midostaurin.
Delamanid Delavirdine	The metabolism of Delamanid can be decreased when combined with Delavirdine.
Delamanid Nefazodone	The metabolism of Delamanid can be decreased when combined with Nefazodone.
Delamanid Ditiocarb	The metabolism of Delamanid can be decreased when combined with Ditiocarb.
Delamanid Telaprevir	The metabolism of Delamanid can be decreased when combined with Telaprevir.